Johnson & Johnson QuickFire Challenges

Johnson & Johnson QuickFire Challenges (Active Series)

Supports global health innovators through recurring Johnson and Johnson QuickFire themed challenges in medicine and life science domains.

Johnson & Johnson Innovation operates the QuickFire Challenges programme as a recurring series of themed competitions targeting specific disease areas, technology domains, or geographies within the life sciences and health technology sectors. The programme has run multiple distinct challenge cycles in the 2025–2026 period, spanning surgical artificial intelligence, drug discovery, neuroscience, urologic oncology, nursing innovation, and data science. Awards are non-dilutive: J&J does not acquire intellectual property or equity from awardees. Individual cycle award pools have ranged from USD 100,000 in themed single-sector challenges to USD 10 million in Blue Knight public-health cycles co-funded with BARDA. Applications are submitted through the jnjquickfire.secure-platform.com portal, and each cycle publishes its own eligibility criteria and application window independently.

Eligibility across the programme umbrella is intentionally broad. Applicants from any country may apply, spanning for-profit companies, non-profits, universities, research institutes, and individual innovators at any stage from ideation through to commercial launch. Cycles co-funded with external partners — including the Singapore Economic Development Board, BARDA, the American Urological Association, and nursing professional associations — may carry geography-specific or sector-specific requirements. The standard award package includes cash funding and mentorship from J&J subject-matter experts; select cycles also provide computing infrastructure such as GPUs, cloud platforms, and machine-learning toolkits, or JLABS incubator membership.

J&J typically announces three to six new challenge cycles per year, drawn from therapeutic and technology areas where the company maintains active R&D investment. Between active cycles, the programme portal at jnjinnovation.com/innovation-challenges lists all previous challenges by category, providing a reliable signal of the programme's recurring themes. Organisations with capabilities in surgical AI, oncology, neuroscience, therapeutic protein design, or AI-driven drug discovery have been within scope across multiple past cycles.